drugset
drugset / Trial / NCT05683717

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

NCT05683717 ↗

Phase 1 Recruiting 37 enrolled TransThera Sciences (Nanjing), Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.

Timeline

Start
2023-03-30
Primary completion
2026-10-31
Completion
2028-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject TT-01488 Unknown 50 mg Oral

Indications

B-cell neoplasm